Fred Hutchinson

Younger Hispanic/Latinx patients face many barriers that may limit timely access to chimeric antigen receptor T-cell therapy trials for relapsed or refractory B-cell acute lymphoblastic leukemia, according to retrospective study results.

A chimeric antigen receptor T-cell therapy induced high response rates across a range of B-cell malignancies, according to phase 1 study results presented at ASH Annual Meeting and Exposition.

Christopher Li, MD, PhD, has been named the first associate director of diversity, equity and inclusion for the Fred Hutch/University of Washington Cancer Consortium.

Early clinical trials for the first chimeric antigen receptor T-cell therapies mandated recipients receive rigorous post-treatment monitoring, often requiring inpatient admittance lasting anywhere from 2 to 4 weeks.

Minimal residual disease status appeared to influence outcomes after chimeric antigen receptor T-cell therapy for high-risk chronic lymphocytic leukemia, according to study results.

The Society for Immunotherapy of Cancer announced the inaugural class of Fellows of the Academy of Immuno-Oncology.

The world of cancer cell therapy continues to evolve, and the next breakthrough may include T cells genetically modified to include T-cell receptors that recognize a wider array of tumor-associated antigens.

The world of cancer cell therapy continues to evolve, and the next breakthrough may include T cells genetically modified to include T-cell receptors that recognize a wider array of tumor-associated antigens.

National Comprehensive Cancer Network updated its guidance on COVID-19 vaccination for patients with cancer following FDA authorization of a third mRNA vaccine dose for certain immunocompromised individuals.

Many individuals with cancer lack adequate immune defense against the measles and mumps viruses, according to a study conducted by researchers at Fred Hutchinson Cancer Research Center and published in JAMA Network Open.